MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Last trade$1.37
Day change+$0.03 (+2.24%)
Day range$1.32 – $1.51
Volume48,988
Market cap$69M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$68.65M
Price / earnings
—
Price / book
1.67×
Price / sales
73.37×
EV / sales
42.1×
EV / EBITDA
-3.42×
Profitability
Earnings per share
-$0.21
Return on assets
-23.31%
Return on equity
-25.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.75×
Quick ratio
8.75×
Cash ratio
8.47×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MNOV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$138.56K
$458.44K
$186.98K
$151.74K
$123.32K
$134.6K
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$138.56K
$458.44K
$186.98K
$151.74K
$123.32K
$134.6K
$0
$0
Selling, general and administrative
$1.95M
$1.97M
$1.76M
$1.7M
$1.92M
$1.55M
$1.36M
$1.28M
Research and development
$1.25M
$1.03M
$1.26M
$1.54M
$1.58M
$2.19M
$1.84M
$1.91M
Total operating expenses
$3.2M
$3M
$3.02M
$3.24M
$3.5M
$3.74M
$3.2M
$3.18M
Operating income
-$3.06M
-$2.54M
-$2.84M
-$3.09M
-$3.38M
-$3.61M
-$3.2M
-$3.18M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.84M
-$2.31M
-$2.59M
-$2.8M
-$3.05M
-$3.28M
-$2.86M
-$2.81M
Income taxes
$0
$0
$0
$5.99K
$0
$0
$0
$5.54K
Net income
-$2.84M
-$2.31M
-$2.59M
-$2.8M
-$3.05M
-$3.28M
-$2.86M
-$2.81M
Net income attributable to common shareholders
-$2.84M
-$2.31M
-$2.59M
-$2.8M
-$3.05M
-$3.28M
-$2.86M
-$2.81M
EBITDA
-$3.06M
-$2.54M
-$2.83M
-$3.09M
-$3.38M
-$3.6M
-$3.2M
-$3.18M
Basic earnings per share
-$0.06
-$0.05
-$0.05
-$0.06
-$0.06
-$0.07
-$0.06
-$0.06
Diluted earnings per share
-$0.06
-$0.05
-$0.05
-$0.06
-$0.06
-$0.07
-$0.06
-$0.06
Recent news
Company coverage with links to the original publishers.
MediciNova reported a quarterly loss of $0.06 per share, matching consensus estimates, with revenues of $0.14 million missing expectations by 7.63%. The company has underperformed the S&P 500 year-to-date, gaining 7.6% versus the market's 11.3%. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Gyre Therapeutics reported Q3 2026 earnings of $0.04 per share, beating consensus estimates of a $0.15 loss, with revenues of $32.93 million exceeding expectations by 15.15%. However, the stock has declined 37.1% year-to-date versus the S&P 500's 12.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
MediciNova reported topline results from its Phase 2 trial of MN-001 (tipelukast) for nonalcoholic fatty liver disease and hypertriglyceridemia, which did not achieve statistical significance on primary endpoints but showed encouraging signals including significant improvements in HDL cholesterol and early triglyceride reduction. The company also announced completion of patient enrollment in its Phase 2b/3 COMBAT-ALS trial for MN-166 (ibudilast), with topline results expected by year-end.
MediciNova announced that management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York to meet with investors. The company is developing late-stage clinical programs for inflammatory, fibrotic, and neurodegenerative diseases, with lead asset MN-166 (ibudilast) in trials for ALS, DCM, and MS, and MN-001 (tipelukast) being evaluated for IPF and NAFLD.
MediciNova reported topline results from its Phase 2 MN-001-NATG-202 trial evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD in type 2 diabetes patients. The drug showed statistically significant increases in HDL-C and HDL-P, significant early triglyceride reduction at Week 4, and numerical improvements in body weight and liver fat. MN-001 demonstrated a favorable safety profile, though the company indicated a larger study is needed to further evaluate efficacy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.